PHAT Stock Analysis: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$8.92
0.17 (1.94%)
▲
5d:
-25.36%
30d:
-20.36%
90d:
-25.73%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PHAT is down 25.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PHAT is down 25.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.13
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$8.77
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $8.92, which is considered oversold relative to its 30-day fair value range of $10.12 to $11.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.6) compared to its historical average (7.6). Remarkably, the market is currently pricing in an annual earnings decline of 4.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAT is in a uptrend. Immediate support is located at $8.45, while resistance sits at $12.24.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.40 (+167.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAT is in a uptrend. Immediate support is located at $8.45, while resistance sits at $12.24.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.40 (+167.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.12 -
$11.94
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding PHAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 167.4% below Wall St target ($23.40)
- WARNING: Recommendation downgraded due to -25.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$10.12 -
$11.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.45
Resistance Level
$12.24
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.59
Wall Street Target
$23.40
(+167.4%)
Revenue Growth (YoY)
104.4%
Profit Margin
-76.8%
Valuation Discount vs History
-4.5% cheaper
PE vs Historical
6.6 vs 7.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.5%
(market-implied from PE analysis)
1-Year Target
$8.36
(-5%)
2-Year Target
$7.98
(-9%)
3-Year Target
$7.62
(-13%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$8.78
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.6 to 7.6
Stabilization Target:
$10.08
(+15.2%)
PE Expansion Potential:
+15.2%
Share & Embed Analysis
Last updated: August 03, 2026 2:32 PM ET
Data refreshes hourly during market hours. Next update: 3:32 PM
Data refreshes hourly during market hours. Next update: 3:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
